ArticleBMC women's health2014
Highly-cited estimates of the cumulative incidence and recurrence of vulvovaginal candidiasis are inadequately documented.
Article in BMC women's health, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Treatment for recurrent vulvovaginal candidiasis (thrush).The Cochrane database of systematic reviews · 2022Pooled it
- Comparative phase I randomized open-label pilot clinical trial of GynophilusEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Trial
- Estimated burden of serious mycoses in Poland.Scientific reports · 2025Article
- Migration and standing variation in vaginal and rectal yeast populations in recurrent vulvovaginal candidiasis.mSystems · 2025Article
- Insights and advances in recurrent vulvovaginal candidiasis.PLoS pathogens · 2023Article
- Epidemiological Profile of Patients with Vulvovaginal Candidiasis from a Sexually Transmitted Infection Clinic in Southern Spain.Pathogens (Basel, Switzerland) · 2023Article
- Outpatient Antifungal Prescribing Patterns in the United States, 2018.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2022Article
- Lived experience of medical management in recurrent vulvovaginal candidiasis: a qualitative study of an uncertain journey.BMC women's health · 2022Article
- Survey of incidence, lifetime prevalence, and treatment of self-reported vulvovaginal candidiasis, United States, 2020.BMC women's health · 2022Article
- Article
- Identification of sulfur components enhancing the anti-Candida effect of Lactobacillus rhamnosus Lcr35.Scientific reports · 2020Article
- Public Awareness of Invasive Fungal Diseases - United States, 2019.MMWR. Morbidity and mortality weekly report · 2020Article
- The Burden of Fungal Infections in Ethiopia.Journal of fungi (Basel, Switzerland) · 2019Review
- Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis.Infection and drug resistance · 2018Article
- Fungal Profile of Vulvovaginal Candidiasis in a Tertiary Care Hospital.Journal of clinical and diagnostic research : JCDR · 2017Article
- In vitro activity of Spirulina platensis water extract against different Candida species isolated from vulvo-vaginal candidiasis cases.PloS one · 2017Article
- Distribution and Drug Susceptibility ofJundishapur journal of microbiology · 2016Article
- Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis.Antimicrobial agents and chemotherapy · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAvailable literature concerning the epidemiologic or clinical features of vulvovaginal candidiasis commonly reports that: 75% of women will experience an episode of vulvovaginal candidiasis in their lifetimes, 50% of whom will experience at least a second episode, and 5-10% of all women will experience recurrent vulvovaginal candidiasis (≥4 episodes/1 year). In this debate we traced the three commonly cited statistics to their presumed origins. DISCUSSION: It is apparent that these figures were inadequately documented and lacked supporting epidemiologic evidence. Population-based studies are needed to make reliable estimates of the lifetime risk of vulvovaginal candidiasis and the proportion of women who experience recurrent candidiasis. SUMMARY: The extent to which vulvovaginal candidiasis is a source of population-level morbidity remains uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.